دورية أكاديمية
Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma.
| العنوان: | Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma. |
|---|---|
| المؤلفون: | Porsbjerg CM; Department of Respiratory Medicine and Infectious Diseases, Research Unit, Bispebjerg Hospital, Copenhagen, Denmark., Townend J; Observational and Pragmatic Research Institute, Singapore, Singapore.; Optimum Patient Care Global, Cambridge, United Kingdom., Bergeron C; Department of Medicine, Centre for Lung Health, Vancouver General Hospital, Vancouver, BC, Canada.; Department of Medicine, The University of British Columbia, Vancouver, BC, Canada., Christoff GC; Faculty of Public Health, Medical University, Sofia, Bulgaria., Katsoulotos GP; Woolcock Institute of Medical Research, The University of Sydney, Sydney, NSW, Australia.; School of Medicine, Sydney Campus, The University of Notre Dame, Sydney, NSW, Australia., Larenas-Linnemann D; Centro de Excelencia en Asma y Alergia, Hospital Médica Sur, Ciudad de México, Mexico., Tran TN; BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, United States., Al-Lehebi R; Department of Pulmonology, King Fahad Medical City, Riyadh, Saudi Arabia.; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia., Bosnic-Anticevich SZ; Woolcock Institute of Medical Research, The University of Sydney, Sydney, NSW, Australia.; Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia., Busby J; Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom., Hew M; Allergy, Asthma and Clinical Immunology Service, Alfred Health, Melbourne, VIC, Australia.; Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia., Kostikas K; Respiratory Medicine Department, University of Ioannina, Ioannina, Greece., Papadopoulos NG; Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, United Kingdom.; Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece., Pfeffer PE; Department of Respiratory Medicine, Barts Health National Health Services (NHS) Trust, London, United Kingdom.; Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom., Popov TA; University Hospital St. Ivan Rilski, Sofia, Bulgaria., Rhee CK; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea., Sadatsafavi M; Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada., Tsai MJ; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.; Department of Internal Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan., Ulrik CS; Department of Respiratory Medicine, Copenhagen ;University Hospital - Hvidovre, Copenhagen, Denmark., Al-Ahmad M; Microbiology Department, College of Medicine, Kuwait University, Kuwait City, Kuwait.; Al-Rashed Allergy Center, Ministry of Health, Kuwait City, Kuwait., Altraja A; Department of Pulmonology, University of Tartu and Lung Clinic, Tartu University Hospital, Tartu, Estonia., Beastall A; Observational and Pragmatic Research Institute, Singapore, Singapore.; Optimum Patient Care Global, Cambridge, United Kingdom., Bulathsinhala L; Observational and Pragmatic Research Institute, Singapore, Singapore.; Optimum Patient Care Global, Cambridge, United Kingdom., Carter V; Observational and Pragmatic Research Institute, Singapore, Singapore.; Optimum Patient Care Global, Cambridge, United Kingdom., Cosio BG; Son Espases University Hospital-Institut d'Investigació Sanitària Illes Balears (IdISBa)-Ciberes, Mallorca, Spain., Fletton K; Observational and Pragmatic Research Institute, Singapore, Singapore.; Optimum Patient Care Global, Cambridge, United Kingdom., Hansen S; Respiratory Research Unit, Bispebjerg University Hospital, Copenhagen, Denmark.; Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark., Heaney LG; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom., Hubbard RB; Observational and Pragmatic Research Institute, Singapore, Singapore.; Optimum Patient Care Global, Cambridge, United Kingdom.; Respiratory Medicine at the School of Medicine, University of Nottingham, Nottingham, United Kingdom., Kuna P; Division of Internal Medicine Asthma and Allergy, Medical University of Lodz, Lodz, Poland., Murray RB; Optimum Patient Care Global, Cambridge, United Kingdom., Nagano T; Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan., Pini L; Department of Clinical and Experimental Sciences - University of Brescia, Spedali Civili di Brescia, Brescia, Italy., Cano Rosales DJ; Instituto Neumológico del Oriente, Bucaramanga, Colombia., Schleich F; Centre Hospitalier Universitaire (CHU) Sart-Tilman, GIGA I3, University of Liege, Liège, Belgium., Wechsler ME; Department of Medicine, National Jewish Health (NJH) Cohen Family Asthma Institute, National Jewish Health, Denver, CO, United States., Amaral R; Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.; CINTESIS@RISE, MEDCIDS, Faculty of Medicine of the University of Porto, Porto, Portugal., Bourdin A; PhyMedExp, Univ Montpellier, National Center for Scientific Research (CNRS), The National Institute of Health and Medical Research (INSERM), Centre Hospitalier Universitaire (CHU) Montpellier, Montpellier, France., Brusselle GG; Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.; Departments of Epidemiology and Respiratory Medicine, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands., Chen W; Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore., Chung LP; Department of Respiratory Medicine, Fiona Stanley Hospital, Perth, WA, Australia., Denton E; Allergy, Asthma and Clinical Immunology Service, Alfred Health, Melbourne, VIC, Australia.; Department of Medicine, Central Clinical School, Monash University, Melbourne, VIC, Australia., Fonseca JA; CINTESIS@RISE, MEDCIDS, Faculty of Medicine of the University of Porto, Porto, Portugal., Hoyte F; Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Health, Denver, CO, United States., Jackson DJ; Guy's Severe Asthma Centre, Guy's Hospital, King's College London, London, United Kingdom., Katial R; Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Health, Denver, CO, United States., Kirenga BJ; Department of Medicine, Lung Institute, Makerere University Lung Institute, Kampala, Uganda., Koh MS; Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore, Singapore., Ławkiedraj A; Medical University of Lodz, Lodz, Poland., Lehtimäki L; Allergy Centre, Tampere University Hospital, Tampere, Finland.; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Liew MF; FAST and Chronic Programmes, Alexandra Hospital, National University Health System, Singapore, Singapore.; Division of Respiratory and Critical Care Medicine, Department of Medicine, National University Hospital, National University Health System, Singapore, Singapore., Mahboub B; Rashid Hospital, Dubai Health Authority (DHA), Dubai, United Arab Emirates.; Dubai Academic and Health Corporation, Dubai, United Arab Emirates., Martin N; BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, United States.; Department of Respiratory Medicine, University of Leicester, Leicester, United Kingdom., Menzies-Gow AN; BioPharmaceutical Medical, AstraZeneca, Cambridge, United Kingdom.; Lung Division, Royal Brompton and Harefield Hospital, London, United Kingdom., Pang PH; Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore, Singapore., Papaioannou AI; 2nd Respiratory Medicine Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece., Patel PH; Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom., Perez-De-Llano L; Pneumology Service, Lucus Augusti University Hospital, Sergas (Galician Healthcare Service) Integrated Management Structure (EOXI) Lugo, Cervo, Spain., Peters MJ; Department of Thoracic Medicine, Concord Hospital, Sydney, NSW, Australia.; Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia., Ricciardi L; Allergy and Clinical Immunology, G. Martino Hospital, University of Messina, Messina, Italy., Rodríguez-Cáceres B; Instituto Neumológico del Oriente, Bucaramanga, Colombia., Solarte I; Pulmonary Unit, Hospital Universitario San Ignacio, Bogotá, Colombia.; School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia., Tay TR; Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore, Singapore., Torres-Duque CA; Centro Internacional de Investigación en Neumología (CINEUMO), Respiratory Research Center, Fundación Neumológica Colombiana, Bogotá, Colombia.; Universidad de La Sabana, Doctoral Biosciences, Chia, Colombia., Wang E; Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Health, Denver, CO, United States.; Division of Allergy and Clinical Immunology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, United States., Zappa M; Department of Medicine and Surgery, University of Insubria, Varese, Italy., Abisheganaden J; Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore, Singapore.; Health Services and Outcomes Research, National Healthcare Group, Singapore, Singapore.; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore., Assing KD; Department of Respiratory Medicine, Aalborg University Hospital, Aalborg, Denmark., Costello RW; Department of Respiratory Medicine, Clinical Research Centre, Smurfit Building Beaumont Hospital, Royal College of Surgeons Ireland (RCSI), Dublin, Ireland., Gibson PG; Australian Severe Asthma Network, Priority Research Centre for Healthy Lungs, University of Newcastle, Newcastle, NSW, Australia.; Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, John Hunter Hospital, Newcastle, NSW, Australia., Heffler E; Personalized Medicine, Asthma and Allergy, Istituto Clinico Humanitas, Humanitas Cancer Center (IRCCS) Humanitas Research Hospital, Rozzano, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy., Máspero J; Clinical Research for Allergy and Respiratory Medicine, CIDEA Foundation, Buenos Aires, Argentina.; University Career of Specialists in Allergy and Clinical Immunology at the Buenos Aires University School of Medicine, Buenos Aires, Argentina., Nicola S; Allergy and Immunology Unit, L'Azienda Ospedaliera (AO) Ordine Mauriziano di Torino, Turin, Italy., Perng Steve DW; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan., Puggioni F; Personalized Medicine, Asthma and Allergy, Istituto Clinico Humanitas, Humanitas Cancer Center (IRCCS) Humanitas Research Hospital, Rozzano, Italy., Salvi S; Pulmocare Research and Education Foundation, Pune, India., Sheu CC; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.; Department of Internal Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan., Sirena C; Severe Asthma Network Italy (SANI), Milano, Italy., Taillé C; Department of Respiratory Diseases, Bichat Hospital, l'Assistance publique - Hôpitaux de Paris (AP-HP) Nord-Université Paris Cité, Paris, France., Tan TL; Department of Family Medicine, National University Health System, Singapore, Singapore., Bjermer L; Respiratory Medicine and Allergology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden., Canonica GW; Personalized Medicine, Asthma and Allergy, Istituto Clinico Humanitas, Humanitas Cancer Center (IRCCS) Humanitas Research Hospital, Rozzano, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy., Iwanaga T; Kindai University Hospital, Osakasayama, Japan., Jiménez-Maldonado L; Fundación Neumológica Colombiana, ASMAIRE REXPIRA (Atención integral y rehabilitación en asma or Comprehensive Care and Rehabilitation in Asthma) Program, Bogotá, Colombia.; Universidad de La Sabana, Doctoral Biosciences, Chia, Colombia., Taube C; Department of Pulmonary Medicine, University Medical Center Essen-Ruhrlandklinik, Essen, Germany., Brussino L; Department of Medical Sciences, University of Turin, Turin, Italy., Price DB; Observational and Pragmatic Research Institute, Singapore, Singapore.; Optimum Patient Care Global, Cambridge, United Kingdom.; Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom. |
| المصدر: | Frontiers in immunology [Front Immunol] 2024 Apr 19; Vol. 15, pp. 1361891. Date of Electronic Publication: 2024 Apr 19 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Multicenter Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Asthma*/drug therapy , Asthma*/diagnosis , Asthma*/immunology , Biomarkers* , Immunoglobulin E*/blood , Immunoglobulin E*/immunology , Eosinophils*/immunology , Biological Products*/therapeutic use, Humans ; Male ; Female ; Middle Aged ; Adult ; Anti-Asthmatic Agents/therapeutic use ; Treatment Outcome ; Registries ; Severity of Illness Index ; Leukocyte Count ; Nitric Oxide/metabolism ; Aged ; Cohort Studies |
| مستخلص: | Background: To date, studies investigating the association between pre-biologic biomarker levels and post-biologic outcomes have been limited to single biomarkers and assessment of biologic efficacy from structured clinical trials. Aim: To elucidate the associations of pre-biologic individual biomarker levels or their combinations with pre-to-post biologic changes in asthma outcomes in real-life. Methods: This was a registry-based, cohort study using data from 23 countries, which shared data with the International Severe Asthma Registry (May 2017-February 2023). The investigated biomarkers (highest pre-biologic levels) were immunoglobulin E (IgE), blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO). Pre- to approximately 12-month post-biologic change for each of three asthma outcome domains (i.e. exacerbation rate, symptom control and lung function), and the association of this change with pre-biologic biomarkers was investigated for individual and combined biomarkers. Results: Overall, 3751 patients initiated biologics and were included in the analysis. No association was found between pre-biologic BEC and pre-to-post biologic change in exacerbation rate for any biologic class. However, higher pre-biologic BEC and FeNO were both associated with greater post-biologic improvement in FEV Conclusions: The ability of higher baseline BEC, FeNO and their combination to predict biologic-associated lung function improvement may encourage earlier intervention in patients with impaired lung function or at risk of accelerated lung function decline. Competing Interests: CP has attended advisory boards for AstraZeneca, Novartis, TEVA, and Sanofi-Genzyme; has given lectures at meetings supported by AstraZeneca, Novartis, TEVA, Sanofi-Genzyme, and GlaxoSmithKline; has taken part in clinical trials sponsored by AstraZeneca, Novartis, MSD, Sanofi-Genzyme, GlaxoSmithKline, and Novartis; and has received educational and research grants from AstraZeneca, Novartis, TEVA, GlaxoSmithKline, ALK, and Sanofi-Genzyme. JT is an employee of the Observational and Pragmatic Research Institute OPRI. OPRI conducted this study in collaboration with Optimum Patient Care and AstraZeneca. CB reports advisory board participation of Sanofi-Regeneron, AstraZeneca, Takeda, ValeoPharma, honorarium for presentations for AstraZeneca/Amgen, GlaxoSmithKline, Grifols, Sanofi-Regeneron, ValeoPharma and grants paid to UBC from BioHaven, Sanofi-Regeneron, AstraZeneca, GlaxoSmithKline. GCC declares relevant research support from AstraZeneca and Sanofi. GK has attended advisory boards for AstraZeneca, GlaxoSmithKline and Chiesi. He has also given lectures at meetings supported by Novartis, Sanofi-Genzyme, AstraZeneca, GlaxoSmithKline, and Boehringer-Ingelheim. DL reports personal fees from ALK-Abelló, AstraZeneca national and global, Bayer, Chiesi, Grunenthal, Grin, GlaxoSmithKline national and global, Viatris, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, Carnot, grants from Abbvie, Bayer, Lilly, Sanofi, AstraZeneca, Pfizer, Novartis, Circassia, UCB, GlaxoSmithKline, outside the submitted work. TNT is an employee of AstraZeneca and may own stock or stock options in AstraZeneca. AstraZeneca is a co-funder of ISAR. RA-L has given lectures at meetings supported by AstraZeneca, Boehringer Ingelheim, Novartis, GlaxoSmithKline, and Sanofi, and participated in advisory board fees from GlaxoSmithKline, AstraZeneca, Novartis, and Abbott. SB-A has received honorarium for participation in expert advisory boards and given lectures for Teva Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Meda, Mundipharma, Sanofi, Mylan and received unrestricted research grants from Mylan, AstraZeneca, Teva, Mundipharma International, GlaxoSmithKline, and Viatris. JB has received research grants from AstraZeneca and personnel fees from NuvoAir, outside the submitted work. MH declares grants and other advisory board fees made to his institutional employer from AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Teva, and Seqirus, for unrelated projects. KK received honoraria for presentations and consultancy fees from AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, ELPEN, Gilead, GlaxoSmithKline, Menarini, Novartis, Sanofi, Specialty Therapeutics, WebMD. His department has received funding and grants from AstraZeneca, Boehringer Ingelheim, Chiesi, Innovis, ELPEN, GlaxoSmithKline, Menarini, Novartis and NuvoAir. NP has been a speaker and/or advisory board member for Abbott, Abbvie, ALK, Asit Biotech, AstraZeneca, Biomay, Boehringer Ingelheim, GlaxoSmithKline, HAL, Faes Farma, Medscape, Menarini, MSD, Novartis, Nutricia, OM Pharma, Regeneron, Sanofi, Takeda, and Viatris. PEP has attended advisory boards for AstraZeneca, GlaxoSmithKline, and Sanofi; has given lectures/webinars at meetings supported by AstraZeneca, Chiesi and GlaxoSmithKline; has taken part in clinical trials sponsored by AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, and Sanofi, for which his institution received remuneration; and has a current research grant funded by GlaxoSmithKline. TP declares relevant research support from Novartis and Chiesi Pharma. CR received consulting/lecture fees from MSD, AstraZeneca, GlaxoSmithKline, Novartis, Takeda, Mundipharma, Boehringer-Ingelheim, Teva, Sanofi, and Bayer. MS has received honoraria from AstraZeneca, Boehringer Ingelheim, Teva, and GlaxoSmithKline for purposes unrelated to the content of this manuscript and has received research funding from AstraZeneca and Boehringer Ingelheim directly into his research account from AstraZeneca for unrelated projects. M-JT has received sponsorship to attend or speak at conferences, honoraria for lecturing or attending advisory boards, and research grants from the following companies: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Shionogi and Orient EuroPharma. CU reports personal fees for talks, participation in advisory boards etc. from AstraZeneca, GlaxoSmithKline, Teva, Boehringer Ingelheim, Orion Pharma, Sanofi Genzyme, TFF Pharmaceuticals, Covis Pharma, Berlin-Chemie, Takeda, Chiesi, and Pfizer, outside the submitted work. MA-A has received advisory board and speaker fees from AstraZeneca, Sanofi, Novartis, and GlaxoSmithKline and received a grant from Kuwait Foundation for the Advancement of Sciences KFAS. AA has received lecture fees from AstraZeneca, Berlin-Chemie Menarini, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, MSD, Norameda, Novartis, Orion, Sanofi, and Zentiva; sponsorships from AstraZeneca, Berlin-Chemie Menarini, Boehringer Ingelheim, GlaxoSmithKline, MSD, Norameda, Novartis, and Sanofi; and has participated in advisory boards for AstraZeneca, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, MSD, Novartis, Sanofi, and Teva. ABe is an employee of Optimum Patient Care Global, a co-funder of the International Severe Asthma Registry. LBu is an employee of the Observational and Pragmatic Research Institute OPRI. OPRI conducted this study in collaboration with Optimum Patient Care and AstraZeneca. VC is an employee of Optimum Patient Care OPC. OPC is a co-funder of the International Severe Asthma Registry. BC declares grants from Chiesi and GlaxoSmithKline; personal fees for advisory board activities from Chiesi, GlaxoSmithKline, Novartis, Sanofi, Teva, and AstraZeneca; and payment for lectures/speaking engagements from Chiesi, Novartis, GlaxoSmithKline, Menarini, and AstraZeneca, outside the submitted work. KF is an employee of Optimum Patient Care Global OPCG, a co-funder of the International Severe Asthma Registry. LH has received grant funding, participated in advisory boards and given lectures at meetings supported by Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Hoffmann la Roche, GlaxoSmithKline, Novartis, Theravance, Evelo Biosciences, Sanofi, and Teva; he has received grants from MedImmune, Novartis UK, Roche/Genentech Inc, and GlaxoSmithKline, Amgen, Genentech/Hoffman la Roche, AstraZeneca, MedImmune, GlaxoSmithKline, Aerocrine, and Vitalograph; he has received sponsorship for attending international scientific meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Napp Pharmaceuticals; he has also taken part in asthma clinical trials sponsored by AstraZeneca, Boehringer Ingelheim, Hoffmann la Roche, and GlaxoSmithKline for which his institution received remuneration; he is the Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma which involves industrial partnerships with a number of pharmaceutical companies including Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann la Roche, and Janssen. RH is an employee for Observational and Pragmatic Research Institute OPRI which conducted this study in collaboration with Optimum Patient Care and AstraZeneca. PK reports personal fees from Adamed, AstraZeneca, Berlin Chemie Menarini, FAES, Glenmark, Novartis, Polpharma, Boehringer Ingelheim, Teva, Zentiva, outside the submitted work. RM is a consultant for Observational and Pragmatic Research Institute OPRI which conducted this study in collaboration with Optimum Patient Care and AstraZeneca. TN received lecture fees from Kyorin, GlaxoSmithKline, Novartis, Sanofi, and AstraZeneca. LP received research grants and lecture fees from GlaxoSmithKline, Menarini, Chiesi, AstraZeneca and Grifols. DC has received speaker fees from AstraZeneca, Boehringer Ingelheim, and has acted as an investigator for trials sponsored by AstraZeneca. FS reports consultancy work for GlaxoSmithKline, AstraZeneca, Sanofi - Advisory board, received speaker fees from GlaxoSmithKline, AstraZeneca, Chiesi, Amgen, Teva and research grants from GlaxoSmithKline, AstraZeneca, and Chiesi. MW reports grants and/or personal fees from Novartis, Sanofi, Regeneron, Genentech, Sentien, Restorbio, Equillium, Genzyme, Cohero Health, Teva, Boehringer Ingelheim, AstraZeneca, Amgen, GlaxoSmithKline, Cytoreason, Cerecor, Sound Biologics, Incyte, and Kinaset. ABo has received industry-sponsored grants from AstraZeneca/MedImmune, Boehringer-Ingelheim, Cephalon/Teva, GlaxoSmithKline, Novartis, Sanofi-Regeneron, and consultancies with AstraZeneca/MedImmune, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Regeneron-Sanofi, Med-in-Cell, Actelion, Merck, Roche, and Chiesi. GB has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Novartis. He is a member of advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, MSD Merck sharp & Dohme, Novartis, and Sanofi/Regeneron. LC has received speaker and consultancy fees and conference expenses from AstraZeneca, Novartis, GlaxoSmithKline, Boehringer Ingelheim and Menarini. ED declares grants to her institution from AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Teva, and Seqirus, for unrelated projects and speaker fees from Sanofi. JF reports grants from research agreements with AstraZeneca, Mundipharma, Sanofi Regeneron, and Novartis. Personal fees for lectures and attending advisory boards: AstraZeneca, GlaxoSmithKline, Mundipharma, Novartis, Sanofi Regeneron, and Teva. FH declares honoraria from AstraZeneca, Sanofi, TEVA, GSK, and Genentech. She has been an investigator on clinical trials sponsored by GlaxoSmithKline, Genentech, and Sanofi, for which her institution has received funding. DJ has received speaker fees and consultancy fees from AstraZeneca, GlaxoSmithKline, Sanofi Regeneron, Boehringer Ingelheim and research funding from AstraZeneca. MK reports grant support from AstraZeneca, and honoraria for lectures and advisory board meetings paid to her hospital Singapore General Hospital from GlaxoSmithKline, AstraZeneca, Novartis, Sanofi and Boehringer Ingelheim, outside the submitted work. LL has received personal fees from ALK, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, Novartis, Orion Pharma and Sanofi. NM is an employee of AstraZeneca and may own stock or stock options in AstraZeneca. AstraZeneca is a co-funder of ISAR. AM-G is an employee of AstraZeneca and may own stock or stock options in AstraZeneca. AstraZeneca is a co-funder of ISAR. PHwP has received honoraria for talks and advisory board meetings from GlaxoSmithKline, AstraZeneca, and Sanofi. AP has received fees and honoraria from Menarini, GlaxoSmithKline, Novartis, Elpen, Boehringer Ingelheim, AstraZeneca, and Chiesi. PHP has received advisory board and speaker fees from AstraZeneca, GlaxoSmithKline, Novartis, and Sanofi/Regeneron. LP-d-L reports grants, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from GlaxoSmithKline, grants, personal fees and non-financial support from Teva, personal fees and non-financial support from Chiesi, grants, personal fees and non-financial support from Sanofi, personal fees from MSD, personal fees from Techdow Pharma, grants, personal fees and non-financial support from Faes Farma, personal fees from Leo-Pharma, grants and personal fees from Gebro, personal fees from Gilead, outside the submitted work. MP declares personal fees and non-financial support from AstraZeneca, GlaxoSmithKline, and Sanofi. LR received fees as a speaker from AstraZeneca, GlaxoSmithKline, Novartis, and Sanofi. IS has received fees as advisory board participant and/or speaker from GlaxoSmithKline and Sanofi. CT-D has received fees as advisory board participant and/or speaker from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, and Sanofi-Aventis; has taken part in clinical trials from AstraZeneca, Novartis, and Sanofi-Aventis; has received unrestricted grants for investigator-initiated studies at Fundacion Neumologica Colombiana from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Grifols and Novartis. EW has received honoraria from AstraZeneca, GlaxoSmithKline, and Genentech. She has been an investigator on studies sponsored by AstraZeneca, GlaxoSmithKline, Genentech, Sanofi, Novartis, and Teva, for which her institution has received funding. RC has received honoraria for lectures from Aerogen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Teva. He is a member of advisory boards for GlaxoSmithKline and Novartis, has received grant support from GlaxoSmithKline and Aerogen and has patents in the use of acoustics in the diagnosis of lung disease, assessment of adherence and prediction of exacerbations. PG has received speaker fees and grants to his institution from AstraZeneca, GlaxoSmithKline, and Novartis. EH declares personal fees for advisory boards participation and/or speaker activities from: Sanofi, Regeneron, GlaxoSmithKline, Novartis, AstraZeneca, Stallergenes-Greer, Circassia, Bosch, Celltrion-Healthcare, Chiesi, and Almirall. JM reports speaker fees, grants or advisory boards for AstraZeneca, Sanofi, GlaxoSmithKline, Novartis, Inmunotek, Menarini and Noucor. D-WP received sponsorship to attend or speak at international meetings, honoraria for lecturing or attending advisory boards, and research grants from the following companies: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Daiichi Sankyo, Shionogi, and Orient Pharma. FP reports having received lectures or advisory board fees from: Menarini, Mundipharma, Chiesi, Alk Abello, AstraZeneca, Boehringer Ingelheim, Guidotti, Malesci, GlaxoSmithKline, Hal Allergy, Novartis, Sanofi, Regeneron, Stallergenes Greer, Valeas, and Almirall. SS declares research support and speaker fees from Cipla, Glenmark, and GlaxoSmithKline. C-CS has received speaker fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Pfizer, and has acted as an investigator for trials sponsored by AstraZeneca, Novartis, Roche, Sanofi-Regeneron, Galapagos, Shionogi, Aridis, Bristol Myers Squibb, Insmed, United Therapeutics, Enanta Pharmaceuticals, Areteia Therapeutics, Meiji, and Horizon Therapeutics. CT has received lecture or advisory board fees and grants to her institution from AstraZeneca, Sanofi, GlaxoSmithKline, Chiesi and Novartis, for unrelated projects. TT is an advisory Board Member for Boehringer Ingelheim, AstraZeneca, Takeda, GlaxoSmithKline, MSD, Mundipharma, and Janssen. Honoraria were received for these advisory boards. Honoraria were received for speaking at CMEs for AstraZeneca in the past. Conference sponsorships from AstraZeneca, Boehringer Ingelheim, Merck Serono, GlaxoSmithKline, Norvatis, Mundipharma and MSD. Research grants from Merck Serono Concor Study, MSD Apbord study. LBj has in the last three years received lecture or advisory board fees from Alk-Abello, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, Sanofi, Genzyme/Regeneron, and Teva. GWC has received research grants, as well as lecture or advisory board fees from A. Menarini, Alk-Albello, Allergy Therapeutics, Anallergo, AstraZeneca, MedImmune, Boehringer Ingelheim, Chiesi Farmaceutici, Circassia, Danone, Faes, Genentech, Guidotti Malesci, GlaxoSmithKline, Hal Allergy, Merck, MSD, Mundipharma, Novartis, Orion, Sanofi Aventis, Sanofi, Genzyme/Regeneron, Stallergenes, UCB Pharma, Uriach Pharma, Teva, Thermo Fisher, and Valeas. TI received speaker bureau fees from Kyorin, GlaxoSmithKline, Novartis, Boehringer Ingelheim, AstraZeneca and Sanofi. LJ-M has received fees as advisory board participant and/or speaker from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, and Sanofi-Aventis; has participated in clinical trials for AstraZeneca, Novartis, and GlaxoSmithKline. DP has advisory board membership with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Viatris, Teva Pharmaceuticals; consultancy agreements with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Viatris, Teva Pharmaceuticals; grants and unrestricted funding for investigator-initiated studies conducted through Observational and Pragmatic Research Institute Pte Ltd from AstraZeneca, Chiesi, Viatris, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, and UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Commune Digital, GlaxoSmithKline, Medscape, Viatris, Novartis, Regeneron Pharmaceuticals and Sanofi Genzyme, Teva Pharmaceuticals; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Novartis, Medscape, Teva Pharmaceuticals; stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd Australia and UK and 92.61% of Observational and Pragmatic Research Institute Pte Ltd Singapore; 5% shareholding in Timestamp which develops adherence monitoring technology; is peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation Programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Porsbjerg, Townend, Bergeron, Christoff, Katsoulotos, Larenas-Linnemann, Tran, Al-Lehebi, Bosnic-Anticevich, Busby, Hew, Kostikas, Papadopoulos, Pfeffer, Popov, Rhee, Sadatsafavi, Tsai, Ulrik, Al-Ahmad, Altraja, Beastall, Bulathsinhala, Carter, Cosio, Fletton, Hansen, Heaney, Hubbard, Kuna, Murray, Nagano, Pini, Cano Rosales, Schleich, Wechsler, Amaral, Bourdin, Brusselle, Chen, Chung, Denton, Fonseca, Hoyte, Jackson, Katial, Kirenga, Koh, Ławkiedraj, Lehtimäki, Liew, Mahboub, Martin, Menzies-Gow, Pang, Papaioannou, Patel, Perez-De-Llano, Peters, Ricciardi, Rodríguez-Cáceres, Solarte, Tay, Torres-Duque, Wang, Zappa, Abisheganaden, Assing, Costello, Gibson, Heffler, Máspero, Nicola, Perng (Steve), Puggioni, Salvi, Sheu, Sirena, Taillé, Tan, Bjermer, Canonica, Iwanaga, Jiménez-Maldonado, Taube, Brussino and Price.) |
| References: | Thorax. 2010 Dec;65(12):1039-44. (PMID: 20671307) J Allergy Clin Immunol. 2004 Jan;113(1):59-65. (PMID: 14713908) Am J Respir Crit Care Med. 2024 Feb 1;209(3):262-272. (PMID: 38016003) Pragmat Obs Res. 2023 Oct 20;14:127-147. (PMID: 37881411) N Engl J Med. 2021 May 13;384(19):1800-1809. (PMID: 33979488) Lancet Respir Med. 2021 Jan;9(1):69-84. (PMID: 32918892) Am J Respir Crit Care Med. 2013 Apr 15;187(8):804-11. (PMID: 23471469) Am J Respir Crit Care Med. 2021 Apr 1;203(7):809-821. (PMID: 33326352) Thorax. 2016 Feb;71(2):187-9. (PMID: 26205878) Lancet. 2016 Jul 2;388(10039):31-44. (PMID: 27130691) Curr Med Chem. 2011;18(10):1423-31. (PMID: 21434851) Ann Allergy Asthma Immunol. 2011 Dec;107(6):474-9. (PMID: 22123375) J Allergy Clin Immunol Pract. 2021 Jul;9(7):2680-2688.e7. (PMID: 33744476) Clin Chest Med. 2019 Mar;40(1):13-28. (PMID: 30691708) Allergy. 2022 Jun;77(6):1786-1796. (PMID: 34913186) Multidiscip Respir Med. 2021 Oct 04;16(1):785. (PMID: 34733505) Lancet Respir Med. 2016 Jul;4(7):549-556. (PMID: 27177493) World Allergy Organ J. 2021 Mar 05;14(3):100520. (PMID: 33747341) J Allergy Clin Immunol Pract. 2019 Jan;7(1):156-164.e1. (PMID: 29800752) J Allergy Clin Immunol Pract. 2023 Apr;11(4):1213-1220.e2. (PMID: 36535524) Chest. 2021 Sep;160(3):814-830. (PMID: 33887242) Eur Respir J. 1999 Oct;14(4):902-7. (PMID: 10573240) BMC Med Res Methodol. 2020 Aug 14;20(1):212. (PMID: 32819285) J Allergy Clin Immunol. 2016 May;137(5):1347-58. (PMID: 27155030) Clin Ther. 2019 Oct;41(10):1956-1971. (PMID: 31563391) Lancet Respir Med. 2020 May;8(5):461-474. (PMID: 32066536) Thorax. 2023 Jul;78(7):643-652. (PMID: 35922128) Semin Respir Crit Care Med. 2022 Oct;43(5):635-645. (PMID: 35253144) Chest. 2016 Oct;150(4):799-810. (PMID: 27018175) Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619841274. (PMID: 31002021) Respir Med. 2010 Jun;104(6):917-20. (PMID: 20227269) Chest. 2015 Dec;148(6):1489-1496. (PMID: 26226215) Science. 1977 Nov 18;198(4318):679-84. (PMID: 333584) Respir Med. 2012 Nov;106(11):1494-500. (PMID: 22884459) World Allergy Organ J. 2021 Sep 21;14(9):100547. (PMID: 34611471) Front Immunol. 2022 Sep 21;13:941492. (PMID: 36211434) Cell Rep Med. 2022 Dec 20;3(12):100857. (PMID: 36543110) Lancet. 2016 Oct 29;388(10056):2128-2141. (PMID: 27609406) J Allergy Clin Immunol. 2015 Oct;136(4):1125-7.e4. (PMID: 26104221) Allergy. 2019 Oct;74(10):1835-1851. (PMID: 30953574) Thorax. 2023 Nov;78(11):1138-1141. (PMID: 37657926) Chest. 2020 Apr;157(4):790-804. (PMID: 31785254) Eur Respir J. 2023 Dec 14;62(6):. (PMID: 37857423) Eur Respir J. 2011 Sep;38(3):561-6. (PMID: 21406508) Eur Respir J. 2007 Sep;30(3):411-3. (PMID: 17766631) Curr Opin Allergy Clin Immunol. 2023 Feb 1;23(1):29-35. (PMID: 36539380) J Allergy Clin Immunol Pract. 2022 May;10(5):1202-1216.e23. (PMID: 34990866) Respir Med. 2020 Nov;173:106156. (PMID: 32979621) Chest. 2020 Apr;157(4):805-814. (PMID: 31838187) Lancet Respir Med. 2018 Jan;6(1):51-64. (PMID: 28919200) Chest. 2024 Feb;165(2):253-266. (PMID: 37925144) Allergy. 2009 Dec;64(12):1780-7. (PMID: 19627273) J Allergy Clin Immunol Pract. 2023 Dec;11(12):3629-3637. (PMID: 37558162) Chest. 2023 Jun;163(6):1368-1379. (PMID: 36740095) |
| فهرسة مساهمة: | Keywords: FEV1; FeNO (Fraction of exhaled Nitric Oxide); biologics; biomarkers; eosinophil (EOS); personalized medicine (PM); severe asthma |
| المشرفين على المادة: | 0 (Biomarkers) 37341-29-0 (Immunoglobulin E) 0 (Biological Products) 0 (Anti-Asthmatic Agents) 31C4KY9ESH (Nitric Oxide) |
| تواريخ الأحداث: | Date Created: 20240507 Date Completed: 20240507 Latest Revision: 20240617 |
| رمز التحديث: | 20240617 |
| مُعرف محوري في PubMed: | PMC11070939 |
| DOI: | 10.3389/fimmu.2024.1361891 |
| PMID: | 38711495 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1361891 |